NCT06413537View on ClinicalTrials.gov

Study of SPG601 in Adult Men With Fragile X Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 5, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Fragile X Syndrome
Interventions
DRUG

SPG601

synthetic small molecule

DRUG

Placebo

Placebo

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors

Lead Sponsor

Spinogenix

Collaborators (1)

Avance Clinical Pty Ltd.
All Listed Sponsors
collaborator

Avance Clinical Pty Ltd.

INDUSTRY

lead

Spinogenix

INDUSTRY